AllSci News
Aprea Therapeutics secures Australian and Japanese patents for WEE1 and ATR inhibitor cancer programs
Aprea Therapeutics, Inc. (Nasdaq: APRE), a clinical-stage biopharmaceutical company headquartered in the US, announced the expansion of its global...
OPKO Health and Entera Bio Expand $50M Oral Peptide Therapy Partnership
OPKO Health, Entera Bio Expand Partnership to Advance Oral Peptide Therapies
CStone Pharmaceuticals' CS2009 shows 90% response rate in first-line non-small cell lung cancer
CStone Pharmaceuticals, the Suzhou-based oncology company listed on the Hong Kong Stock Exchange, reported Phase I/II data for its CS2009 trispecific...
Theriva Biologics' VCN-01 gains FDA agreement on Phase III design for metastatic pancreatic cancer
Theriva Biologics (NYSE American: TOVX), a Rockville, Maryland–based clinical-stage company, announced that the US FDA has agreed to the proposed design of...
Novartis to acquire Synnovation Therapeutics PI3Kα inhibitor program for up to USD 3b.
Novartis has agreed to acquire Pikavation Therapeutics, a wholly-owned subsidiary of Synnovation Therapeutics, to gain control of SNV4818 and related PI3Kα...
INOVIO and Akeso Partner on Glioblastoma Combination Therapy in Phase 2 Clinical Collaboration
INOVIO Pharmaceuticals (Plymouth Meeting, PA) and Akeso, Inc. (Zhongshan, China) announced a clinical collaboration on March 4, 2026, to evaluate a...
Sinopia Biosciences receives NCI grant to apply LEADS metabolomics platform to oncology drug discovery
Sinopia Biosciences, a privately held biotechnology company headquartered at JLABS San Diego, announced in March 2026 that it has been awarded a research...
Polaryx Therapeutics Secures FDA Fast Track Designation for PLX-200 Targeting Rare CLN2 Disease
Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company headquartered in Paramus, New Jersey, announced that the U.S. Food and...
Sanofi's amlitelimab meets Phase III endpoints in atopic dermatitis with extended 12-week dosing interval
Sanofi (NASDAQ: SNY) reported Phase III data from three trials of amlitelimab in moderate-to-severe atopic dermatitis, showing that the anti-OX40L antibody...
NMPA Approves IND for HBM7575/SKB575 by Harbour BioMed and Kelun-Biotech in Atopic Dermatitis
China's NMPA Clears IND for HBM7575/SKB575, a Bispecific Antibody Targeting TSLP in Atopic Dermatitis
Meiji Seika Pharma initiates phase I trial of ME3241, a PD-1 agonist antibody for autoimmune disease
Meiji Seika Pharma has initiated a Phase I clinical trial in Australia evaluating ME3241, an anti-PD-1 agonist monoclonal antibody intended for autoimmune...
CounterX licenses fentanyl antibody and vaccine portfolio from University of Minnesota and Washington
CounterX Therapeutics (Seattle, WA) has executed an exclusive licensing agreement with the University of Minnesota (Minneapolis, MN) and the University of...
FDA Approves Venclexta Plus Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia: AbbVie
The US FDA has approved a supplemental new drug application for the combination of Venclexta (venetoclax) and acalabrutinib for the treatment of previously...
Edding Genor's EDP167 Enters Phase II Trial in Growing Race to Silence ANGPTL3
Edding Genor Group Holdings Limited, the Hong Kong-listed specialty pharmaceutical company, has completed a first-in-human Phase I study of EDP167, a...
Diamyd Medical Secures Crucial US Patent for Intralymphatic Type 1 Diabetes Immunotherapy Approach
Diamyd Medical Secures Key US Patent Protection for Intralymphatic Type 1 Diabetes Immunotherapy Approach
The AllSci Brief
Systematic R&D and deal news. Daily.